Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. These include coronary stents, carotid stents, peripheral stents, bioresorbable or bioabsorbable stents, and renal stents. News included clinical trial data and new technology advances in stents.

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018

February 13, 2018 — Abbott announced the first patient has been enrolled in a...

12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018

February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s...

Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018

January 25, 2018 – Data presented at the Biotronik-sponsored...

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018

January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling...

West Hills Hospital & Medical Center Ranked No. 1 in Los Angeles County for Door-to-Balloon Time
News | Stents Bifurcation | January 18, 2018

January 18, 2018 – West Hills Hospital & Medical Center, a full-service acute care...

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell

There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...

FDA Approves New Indication for NuMed CP Stent System
Technology | Stents Bare Metal | December 14, 2017

December 14, 2017 — The U.S. Food and Drug Administration (FDA) announced clearance for NuMed’s Cheatham Platinum (...

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017

December 13, 2017 — Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug...

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017

November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting,...

Videos | Stents Bifurcation | November 15, 2017

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at...

News | Stents | November 10, 2017

November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive...

The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017

November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience...

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report...

Videos | Stents Bioresorbable | November 07, 2017

A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-...

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

November 6, 2017 —  The first trial to evaluate the safety of...

Overlay Init